Emerging treatments for narcolepsy and its related disorders

Bibliography

• Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369(9560):499-511
   PubMed Web of Science ®Google Scholar
• American Narcolepsy Association. Stimulant medication survey. The Eye Opener 1992: January 1-3
   Google Scholar
• Morgenthaler TI, Kapur VK, Brown T, Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30(12):1705-11
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98(3):365-76
   PubMed Web of Science ®Google Scholar
• Mignot E, Lammers GJ, Ripley B, The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59(10):1553-62
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355(9197):39-40
   PubMed Web of Science ®Google Scholar
• ICSD-2, editor, ICSD-2-International classification of sleep disorders. Diagnostic and coding manual. American Academy of Sleep Medicine. 2nd edition. Westchester, Illinois; 2005
   Google Scholar
• Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications In the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9(4):269-310
   PubMed Web of Science ®Google Scholar
• Hublin C, Kaprio J, Partinene M, The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994;35:709-16
   PubMed Web of Science ®Google Scholar
• Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(Suppl 1):S16-22
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Rogers AE, Walsleben JA, Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22(6):757-65
   PubMed Web of Science ®Google Scholar
• Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, editors, HLA in Narcolepsy. Springer-Verlag, New York; 1988. p. 24-57
   Google Scholar
• Gelb M, Guilleminault C, Kraemer H, Stability of cataplexy over several months-information for the design of therapeutic trials. Sleep 1994;17:265-73
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Mignot E, CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res 2002;110(1):1-7
   PubMed Web of Science ®Google Scholar
• Walterfang M, Upjohn E, Velakoulis D. Is schizophrenia associated with narcolepsy? Cogn Behav Neurol 2005;18(2):113-8
   PubMed Web of Science ®Google Scholar
• Koffel E, Watson D. Unusual sleep experiences, dissociation, and schizotypy: evidence for a common domain. Clin Psychol Rev 2009;29(6):548-59
   PubMed Web of Science ®Google Scholar
• Hishikawa Y, Wakamatsu H, Furuya E, Sleep satiation in narcoleptic patients. Electroencephalogr Clin Neurophysiol 1976;41:1-18
   PubMedGoogle Scholar
• Broughton R, Dunham W, Newman J, Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroencephalogr Clin Neurophysiol 1988;70:473-81
   PubMedGoogle Scholar
• Montplaisir J, Billard M, Takahashi S, Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978;13(1):78-89
   Google Scholar
• Godbout R, Montplaisir J. Comparison of sleep parameters in narcoleptics with and without periodic movements of sleep. In: Koella WP, Ruther E, Schulz H, editors, Sleep '84. Fischer Verlag, Gustav; 1985. p. 380-2
   Google Scholar
• Mosko SS, Shampain DS, Sassin JF. Nocturnal REM latency and sleep disturbance in narcolepsy. Sleep 1984;7:115-25
   PubMed Web of Science ®Google Scholar
• Mayer G, Pollmächer T, Meier-Ewert K, Schulz H. Zur Einschätzung des Behinderungsgrades bei Narkolepsie. Gesundh Wes 1993;55:337-42
   PubMedGoogle Scholar
• Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: Rapid-Eye-Movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992;32(1):3-10
   PubMed Web of Science ®Google Scholar
• Chokroverty S. Sleep apnea in narcolepsy. Sleep 1986;9(1):250-3
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Dement WC, Passouant P, Spectrum Publications, New York; 1976
   Google Scholar
• Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986;9(1):254-9
   PubMed Web of Science ®Google Scholar
• Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 2000;355(9211):1274-5
   PubMed Web of Science ®Google Scholar
• Lammers GJ, Pijl H, Iestra J, Spontaneous food choice in narcolepsy. Sleep 1996;19(1):75-6
   PubMed Web of Science ®Google Scholar
• Mayer G, Hellmann F, Leonhard E, Meier-Ewert K. Circadian temperature and activity rhythms in unmedicated narcoleptic patients. Pharmacol Biochem Behav 1997;58(2):395-402
   PubMed Web of Science ®Google Scholar
• Sachs C, Kaisjer L. Autonomic control of cardiovascular reflexes in narcolepsy. J Neurol Neurosurg Psychiatry 1980;43:535-9
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8
   PubMed Web of Science ®Google Scholar
• Broughton R, Ghanem Q, Hishikawa Y, Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Le J Can Sci Neurol 1981;8(4):299-303
   PubMed Web of Science ®Google Scholar
• Aldrich MS. Automobile accidents in patients with sleep disorders. Sleep 1989;12:487-94
   PubMed Web of Science ®Google Scholar
• Alaila SL. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M, Pollak CP, Cohen FL, Thorpy MJ, Kavey NB, editors, Loss, grief and care: psychosocial aspects of narcolepsy. Haworth Press, New York; 1992. p. 1-22
   Google Scholar
• Broughton R, Ghanem Q. The impact of compound narcolepsy on the life of the patient. In: Guilleminault C, WC D Passouant P, editors, Narcolepsy. Spectrum, New York; 1976. p. 201-20
   Google Scholar
• Roth B, Nevsimalova S. Depression in narcolepsy and hypersomnia. Schweitz Arch Neurol Neurochir Psychiatry 1975;116:291-300
   PubMedGoogle Scholar
• Rogers AE. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nursing 1984;16(6):326-34
   PubMedGoogle Scholar
• Roehrs T, Zorick F, Wittig R, Alerting effects of naps in patients with narcolepsy. Sleep 1986;9(1):194-9
   PubMed Web of Science ®Google Scholar
• Garma L, Marchand F. Non-pharmacological approaches to the treatment of narcolepsy. Sleep 1994;17:S97-S102
   PubMed Web of Science ®Google Scholar
• Nishino S. Modes of action of drugs related to narcolepsy: pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Pandi-Perumal SR, Thorpy MJ, editors, Narcolepsy. Humana, Totowa; 2009. In press
   Google Scholar
• Kuczenski R, Segal DS, Cho AK, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995;15(2):1308-17
   PubMed Web of Science ®Google Scholar
• Snyder SH, Taylor KM, Coyle JT, Meyerhoff JL. The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Am J Psychiatry 1970;127(2):199-207
   PubMed Web of Science ®Google Scholar
• Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17(4):352-71
   PubMed Web of Science ®Google Scholar
• Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991;14(3):218-20
   PubMed Web of Science ®Google Scholar
• Simpson LL. Blood pressure and heart rate responses produced by d-amphetamine: correlation with blood levels of drug. J Pharmacol Exp Ther 1978;205(2):366-73
   PubMed Web of Science ®Google Scholar
• Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704-6
   PubMedGoogle Scholar
• Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975;52:337-53
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol 1974;30:90-3
   PubMed Web of Science ®Google Scholar
• Passouant P, Billiard M. The evolution of narcolepsy with age. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. Spectrum publication, New York; 1976. p. 179-86
   Google Scholar
• Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep 1997;20(1):28-33
   PubMed Web of Science ®Google Scholar
• Auger RR, Goodman SH, Silber MH, Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 2005;28(6):667-72
   PubMed Web of Science ®Google Scholar
• Gonzalez MA, Pentikis HS, Anderl N, Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002;40(4):175-84
   PubMed Web of Science ®Google Scholar
• Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988;12(5):695-700
   PubMed Web of Science ®Google Scholar
• Besset A, Tafti M, Villemin E, Billiard M. The effects of modafinil (300mg) on sleep, sleepiness and arousal in narcoleptic patients. Neurophysiol Clin 1993;23(1):47-60
   PubMedGoogle Scholar
• Boivin DB, Montplaisir J, Petit D, Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993;16(1):46-53
   PubMed Web of Science ®Google Scholar
• Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54(5):1166-75
   PubMed Web of Science ®Google Scholar
• Broughton RJ, Fleming JA, George CF, Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49(2):444-51
   PubMed Web of Science ®Google Scholar
• Wong YN, Simcoe D, Hartman LN, A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999;39(1):30-40
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Simcoe D, Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39(3):281-8
   PubMed Web of Science ®Google Scholar
• Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42(2):123-37
   PubMed Web of Science ®Google Scholar
• Hermant JF, Rambert FA, Deuteil J. Lack of cardiovascular effects after administration of modafinil in conscious monkeys. French Association des Pharmacologistes Tours. Fundam Clin Pharmacol 1991:825
   Google Scholar
• Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 1996;126(4):286-92
   PubMed Web of Science ®Google Scholar
• Edgar DM, Seidel WF, Contreras P, Modafinil promotes EEG wake without intensifying motor activity in the rat. Can J Physiol Pharmacol 1994;72(Suppl 1):362
   Google Scholar
• Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today (Barc) 2008;44(6):395-414
   PubMed Web of Science ®Google Scholar
• Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986;9(1 Pt 2):265-8
   PubMed Web of Science ®Google Scholar
• Nishino S, Mao J, Sampathkumaran R, Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1:49-61, Available from: http://www.sro.org/1998/Nishino/49/
   PubMedGoogle Scholar
• Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998;7(2):92-5
   PubMedGoogle Scholar
• Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004;61(7-8):857-72
   PubMed Web of Science ®Google Scholar
• Rall TR. Central nervous system stimulants. In: Gilman AG, Goodman LS, Rall TW, Murad F, editors, The pharmacological basis of therapeutics. 7th edition. Pergamon Press, New York; 1985. p. 345-82
   Google Scholar
• Kennedy JS, Leduc BW, Scavone JM, Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. J Chromatogr 1987;422:274-80
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995;58(6):684-91
   PubMed Web of Science ®Google Scholar
• Okuro M, Fujiki N, Sokoloff P, Nishino S. Valuations of wake promoting effects of paraxanthine in orexin/ataxin-3 narcoleptic mice Sleep 2009;32(Suppl):A35
   Google Scholar
• Guerreiro S, Toulorge D, Hirsch E, Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 2008;74(4):980-9
   PubMed Web of Science ®Google Scholar
• Huang ZL, Qu WM, Eguchi N, Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005;8(7):858-9
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Snyder M, Aloe FS, Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 1992;15(3):212-16
   PubMed Web of Science ®Google Scholar
• Scrima L, Johnson FH, Thomas EG, Hiller EE. The effects of gamma-hydroxybutyrate (GHB) on multiple sleep latency test (MSLT) in narcolepsy patients; a long term study. Sleep Res 1990;19:288
   Google Scholar
• Scrima L, Hartman PG, Johnson FH Jr, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989;26(4):331-43
   PubMed Web of Science ®Google Scholar
• Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979;6(1):1-6
   PubMed Web of Science ®Google Scholar
• Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report. In: Guilleminault C, Dement WC, Passouant P, editors, Narcolepsy. Spectrum, New York; 1976. p. 59-67
   Google Scholar
• Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;156(4):380-4
   PubMedGoogle Scholar
• Mack RB. Love potion number 8 1/2. Gamma-hydroxybutyrate poisoning. N C Med J 1993;54(5):232-3
   PubMedGoogle Scholar
• Wong CG, Gibson KM, Snead OC III. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004;25(1):29-34
   PubMed Web of Science ®Google Scholar
• Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63(1):1-22
   PubMed Web of Science ®Google Scholar
• Group UXMS. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5(2):119-23
   PubMed Web of Science ®Google Scholar
• Group UXMS. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26(1):31-5
   PubMed Web of Science ®Google Scholar
• Group USXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9
   PubMed Web of Science ®Google Scholar
• Group UXMS. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391-7
   PubMedGoogle Scholar
• Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009;10(4):490-3
   PubMed Web of Science ®Google Scholar
• Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med 2009;11:93-5
   PubMed Web of Science ®Google Scholar
• Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2009; Jul 23
   PubMed Web of Science ®Google Scholar
• Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998;31(6):723-8
   PubMed Web of Science ®Google Scholar
• Andriamampandry C, Taleb O, Viry S, Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J 2003;17(12):1691-3
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. How do antidepressants work? In: Davis JM, Mass JW, editors, The affective disorders. American Psychiatric Press, Wachington, D.C.; 1983. p. 243-60
   Google Scholar
• Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9(2):371-3
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 1986;9(1 Pt 2):280-4
   PubMed Web of Science ®Google Scholar
• Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 1986;74(4):297-303
   PubMed Web of Science ®Google Scholar
• Mignot E, Renaud A, Nishino S, Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993;113(1):76-82
   PubMed Web of Science ®Google Scholar
• Nishino S, Arrigoni J, Shelton J, Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993;16(8):706-12
   PubMed Web of Science ®Google Scholar
• Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault C, Dement WC, Passouant P, editors, Narcolepsy. Spectrum Publication, New York; 1976. p. 625-38
   Google Scholar
• Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986;9(1 Pt 2):285-9
   PubMed Web of Science ®Google Scholar
• Nishino S, Arrigoni J, Shelton J, Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8
   PubMed Web of Science ®Google Scholar
• Kotorii N, Okuro M, Takahashi T, Effects of thyrotropin-releasing hormone analogs in the narcoleptic model mouse. Sleep 2009;32 (Suppl). In press
   Web of Science ®Google Scholar
• Shiba T, Fujiki N, Wisor J, Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004;27(Suppl):A241-A2
   Google Scholar
• Parmentier R, Anaclet C, Guhennec C, The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007;73(8):1157-71
   PubMed Web of Science ®Google Scholar
• Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 2000;23(5):528-38
   PubMed Web of Science ®Google Scholar
• Hallmayer J, Faraco J, Lin L, Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009;41(6):708-11
   PubMed Web of Science ®Google Scholar
• Hecht M, Lin L, Kushida CA, Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003;26(7):809-10
   PubMed Web of Science ®Google Scholar
• Arii J, Kanbayashi T, Tanabe Y, CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 2004;63(12):2440-2
   PubMed Web of Science ®Google Scholar
• Gerashchenko D, Murillo-Rodriguez E, Lin L, Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003;184(2):1010-16
   PubMed Web of Science ®Google Scholar
• Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000;4(5):471-503
   PubMed Web of Science ®Google Scholar
• Steininger TL, Alam MN, Gong H, Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res 1999;840(1-2):138-47
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38(5):715-30
   PubMed Web of Science ®Google Scholar
• Huang ZL, Qu WM, Li WD, Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001;98(17):9965-70
   PubMed Web of Science ®Google Scholar
• Kanbayashi T, Kodama T, Kondo H, CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009;32(2):181-7
   PubMed Web of Science ®Google Scholar
• Nishino S, Sakurai E, Nevsimalova S, Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 2009;32(2):175-80
   PubMed Web of Science ®Google Scholar
• Tedford CE, Edgar DM, Seidel WF, Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy [abstract]. Soc Neurosci 1999;25:1134
   Google Scholar
• Lin JS, Sakai K, Vanni-Mercier G, Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990;523(2):325-30
   PubMed Web of Science ®Google Scholar
• Heuer H, Schafer MK, O'Donnell D, Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol 2000;428(2):319-36
   PubMed Web of Science ®Google Scholar
• Sharp T, Bennett GW, Marsden CA. Thyrotropin-releasing hormone analogues increase dopamine release from slices of rat brain. J Neurochem 1982;39:1763-6
   PubMed Web of Science ®Google Scholar
• Keller HH, Bartholini G, Pletscher A. Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature 1974;248:528-9
   PubMed Web of Science ®Google Scholar
• Vogel HP, Benkert O, Illig R, Psychoendocrinological and therapeutic effects of TRH in depression. Acta Psychiatr Scand 1977;56(3):223-32
   PubMed Web of Science ®Google Scholar
• Bunevicius R, Matulevicius V. Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study. Psychoneuroendocrinology 1993;18(5-6):445-9
   PubMed Web of Science ®Google Scholar
• Broberger C, McCormick DA. Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci 2005;25(7):1664-73
   PubMed Web of Science ®Google Scholar
• Hara J, Gerashchenko D, Wisor JP, Thyrotropin-releasing hormone increases behavioral arousal through modulation of hypocretin/orexin neurons. J Neurosci 2009;29(12):3705-14
   PubMed Web of Science ®Google Scholar
• Gonzalez JA, Horjales-Araujo E, Fugger L, Stimulation of orexin/hypocretin neurones by thyrotropin-releasing hormone. J Physiol 2009;587(Pt 6):1179-86
   PubMed Web of Science ®Google Scholar
• Parmentier R, Kolbaev S, Klyuch BP, Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci 2009;29(14):4471-83
   PubMed Web of Science ®Google Scholar
• Schomburg L, Turwitt S, Prescher G, Human TRH-degrading ectoenzyme cDNA cloning, functional expression, genomic structure and chromosomal assignment. Eur J Biochem 1999;265(1):415-22
   PubMedGoogle Scholar
• Xu YL, Reinscheid RK, Huitron-Resendiz S, Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004;43(4):487-97
   PubMed Web of Science ®Google Scholar
• Porrino LJ, Daunais JB, Rogers GA, Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005;3(9):e299
   PubMed Web of Science ®Google Scholar
• Ehrman LA, Williams MT, Schaefer TL, Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav 2006;5(7):540-51
   PubMed Web of Science ®Google Scholar
• Huang YS, Guilleminault C. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol 2009;41(1):9-16
   PubMed Web of Science ®Google Scholar
• Krogsgaard-Larsen P, Frolund B, Liljefors T, Ebert B. GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol 2004;68(8):1573-80
   PubMed Web of Science ®Google Scholar
• Wisor JP, Pasumarthi RK, Gerashchenko D, Gamma-hydroxybutyrate modifies behavior and GABAergic and catecholaminergic signaling systems in a narcoleptic mouse model Sleep 2009;32(Suppl):A35
   Google Scholar
• Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. JPET 1999;289:219-23
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Fujiki N, Maki RA, Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 2003;346(3):182-6
   PubMed Web of Science ®Google Scholar
• Fujiki N, Ripley B, Yoshida Y, Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003;6(8):953-9
   Google Scholar
• Schatzberg SJ, Barrett J, Cutter Kl, Case study: effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004;18(4):586-8
   PubMed Web of Science ®Google Scholar
• Mieda M, Willie JT, Hara J, Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004;101(13):4649-54
   PubMed Web of Science ®Google Scholar
• Ripley B, Fujiki N, Okura M, Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8(3):525-34
   PubMed Web of Science ®Google Scholar
• Hanson LR, Martinez PM, Taheri S, Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol 2004;4(4):66-71
   Google Scholar
• Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27(52):14239-47
   PubMed Web of Science ®Google Scholar
• Liu M, Thankachan S, Kaur S, Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008;28(7):1382-93
   PubMed Web of Science ®Google Scholar
• Roitberg B, Urbaniak K, Emborg M. Cell transplantation for Parkinson's disease. Neurol Res 2004;26(4):355-62
   PubMed Web of Science ®Google Scholar
• Arias-Carrion O, Murillo-Rodriguez E, Xu M, Transplant of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004;27:1465-70
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27(3):469-74
   PubMed Web of Science ®Google Scholar
• Bjorklund A. Neurobiology. Better cells for brain repair. Nature 1993;362(6419):414-15
   PubMed Web of Science ®Google Scholar
• Asahi S, Egashira S, Matsuda M, Structure-activity relationship stidies on the novel neuropeptide orexin. In: Fujii N, editor, The Japanese peptide society; 2000. p. 37-40
   Google Scholar
• Darker JG, Porter RA, Eggleston DS, Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg Med Chem Lett 2001;11(5):737-40
   PubMed Web of Science ®Google Scholar
• Croston GE, Olsson R, Currier EA, Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). J Med Chem 2002;45(23):4950-3
   PubMed Web of Science ®Google Scholar
• Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 2003;73(6):663-78
   PubMed Web of Science ®Google Scholar
• Saar K, Mazarati AM, Mahlapuu R, Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2002;99(10):7136-41
   PubMed Web of Science ®Google Scholar
• Lecendreux M, Maret S, Bassetti C, Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12(4):347-8
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, River F, IVIG treatment in narcolepsy: report on two new cases. J Sleep Res 2004;13(Suppl 1):167
   Google Scholar
• Zuberi SM, Mignot E, Ling L, MacArthur I. Variable response to intravenous immunoglobulin therapy in childhood necolepsy. J Sleep Res 2004;13(Suppl 1):828
   Google Scholar
• Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007;254(11):1607-8
   PubMed Web of Science ®Google Scholar
• Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58(3):489-90
   PubMed Web of Science ®Google Scholar
• Taheri S, Krempetz M, Jackson M, Autoimmune basis of narcolepsy using western blot analysis of lateral hypothalamus protein extract with serum and cerebrospinal fluid (CSF). Sleep 2003;26(Suppl):A285
   PubMedGoogle Scholar
• Aran A, Nevsimalova S, Plazzi G, Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009;32(8):979-83
   PubMed Web of Science ®Google Scholar
• Mishima K, Fujiki N, Yoshida Y, Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 2008;31(8):1119-26
   PubMed Web of Science ®Google Scholar
• Kanbayashi T, Shimohata T, Nakashima I, Symptomatic narcolepsy in MS and NMO patients; new neurochemical and immunological implications. Arch Neurol 2009. In press
   PubMed Web of Science ®Google Scholar